Antibacterial use in community practice. Assessing quantity, indications and appropriateness, and relationship to the development of antibacterial resistance

Drugs

Volumn 57, Issue 6, 1999, Pages 871-881

  Carrie, Anita G ^a   Zhanel, George G ^a,b  

^a UNIVERSITY OF MANITOBA   (Canada)

^b HEALTH SCIENCES CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; ANTIINFECTIVE AGENT; CEPHALOSPORIN DERIVATIVE; ERYTHROMYCIN; MACROLIDE; PENICILLIN V; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TETRACYCLINE;

ANTIBIOTIC RESISTANCE; AUSTRALIA; CANADA; DRUG USE; HAEMOPHILUS INFLUENZAE; LONGITUDINAL STUDY; RESPIRATORY TRACT INFECTION; REVIEW; STREPTOCOCCUS PNEUMONIAE; UNITED KINGDOM; UNITED STATES;

ANTI-BACTERIAL AGENTS; COMMUNITY MEDICINE; DRUG RESISTANCE, MICROBIAL; DRUG UTILIZATION; HUMANS;

EID: 0033004605     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199957060-00004     Document Type: Review

References (42)

1. 1. Liss RH, Batchelor FR. Economic evaluations of antibiotic use and resistance - a perspective: report of Task Force 6. Rev Infect Dis 1987; 9 Suppl. 3: S297-312
2. 2. Jozefiak ET, Lewicki JE, Kozinn WP. Computer-assisted antimicrobial surveillance in a community teaching hospital. Am J Health Syst Pharm 1995; 52: 1536-40
3. 3. Kunin CM. The responsibility of the infectious disease community for the optimal use of antimicrobial agents. J Infect Dis 1985; 151 (3): 388-98
4. 4. Pestotnik SL, Classen DC, Evans RS, et al. Implementing antibiotic practice guidelines through computer-assisted decision support: clinical and financial outcomes. Ann Intern Med 1996; 124: 884-90
5. 5. Powers DA. Antimicrobial surveillance in a VAMC teaching hospital - resulting cost avoidance. Drug Intell Clin Pharm 1986; 20: 803-5
6. 6. Frighetto L, Nickoloff D, Martinusen SM, et al. Intravenous-to-oral step-down program: four years of experience in a large teaching hospital. Ann Pharmacother 1992; 26: 1447-51
7. 7. Boyter AC, Davey PG, Hudson SA, et al. Evaluation of an antibiotic prescribing protocol for the treatment of acute exacerbations of chronic obstructive airways disease in a hospital respiratory unit. J Antimicrob Chemother 1994; 36: 403-9
8. 8. Marr JJ, Moffet HL, Kunin CM. Guidelines for improving the use of antimicrobial agents in hospital: a statement by the Infectious Diseases Society of America. J Infect Dis 1988; 157: 869-76
9. 9. Working Party of the British Society for Antimicrobial Chemotherapy. Hospital antimicrobial control measures in the UK. J Antimicrob Chemother 1994; 34: 21-42
10. 10. Doern GV. Trends in antimicrobial susceptibility of bacterial pathogens of the respiratory tract. Am J Med 1995; 99 (6B Suppl.): 3S-7S
11. 11. Doern GV, Bruggemann A, Holley HP, et al. Antimicrobial resistance of Streptococcus pneumoniae recovered from outpatients in the United States during the winter months of 1994 to 1995: results of a 30-center national surveillance study. Antimicrob Agents Chemother 1996; 40: 1208-13
12. 12. Simor AE, Louie M, The Canadian Bacterial Surveillance Network, et al. Canadian national survey of prevalence of antimicrobial resistance among clinical isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother 1996; 40: 2190-3
13. 13. Doern GV. Antimicrobial resistance among lower respiratory tract isolates of Haemophilus influenzae: results of a 1992-93 Western Europe and USA collaborative surveillance study. The Alexander Project Collaborative Group. J Antimicrob Chemother 1996; 38 Suppl. A: 59-69
14. 14. Ray WA, Fink R, Schaffner W, et al. Improving antibiotic prescribing in outpatient practice. Med Care 1985; 23: 1307-13
15. 15. Kunin CM. Resistance to antimicrobial drugs - a worldwide calamity. Ann Intern Med 1993; 118: 557-61
16. 16. Col NF, O'Connor RW. Estimating worldwide current antibiotic usage: report of Task Force 1. Rev Infect Dis 1987; 9 Suppl. 3: S232-43
17. 17. Wyatt TD, Passmore CM, Morrow NC, et al. Antibiotic prescribing: the need for a policy in general practice. BMJ 1990; 300: 441-4
18. 18. McGavock H, Webb CH, Johnston GD, et al. Market penetration of new drugs in one United Kingdom region: implications for general practitioners and administrators. BMJ 1993; 307: 1118-20
19. 19. McManus P, Hammond ML, Whicker SD, et al. Antibiotic use in the Australian community, 1990-1995. Med J Aust 1997; 167: 124-7
20. 20. McCaig LF, Hughes JM. Trends in antimicrobial drug prescribing among office-based physicians in the United States. JAMA 1995; 273: 214-9
21. 21. Carrie AG, Zhanel GG. Changing antibiotic use in community practice: results from a Canadian province 1995-1997. Ann Pharmacother. In press
22. 22. Gonzales R, Sande M. What will it take to stop physicians from prescribing antibiotics in acute bronchitis. Lancet 1995; 345: 665-6
23. 23. Hueston WJ. Antibiotics: neither cost effective nor 'cough' effective. J Fam Pract 1997; 44: 261-5
24. 24. McCracken GH. Considerations in selecting an antibiotic for treatment of acute otitis media. Pediatr Infect Dis J 1994; 13: 1054-7
25. 25. Mainous AG, Hueston WJ, Clark JR. Antibiotics and upper respiratory infection. Do some folks think there is a cure for the common cold. J Fam Pract 1996; 42: 357-61
26. 26. Gonzales R, Steiner JF, Sande MA. Antibiotic prescribing for adults with colds, upper respiratory tract infections, and bronchitis by ambulatory care physicians. JAMA 1997; 278: 901-4
27. 27. Nyquist A, Gonzales R, Steiner JF, et al. Antibiotic prescribing for children with colds, upper respiratory tract infections and bronchitis. JAMA 1998; 279: 875-7
28. 28. de Melker RA, Kuyvenhoven MM. Management of upper respiratory tract infections in Dutch family practice. J Fam Pract 1994; 38: 353-7
29. 29. Froom J, Culpepper L, Grob P, et al. Diagnosis and antibiotic treatment of acute otitis media: report from International Primary Care Network. BMJ 19910; 300: 582-6
30. 30. Gleason PP, Kapoor WN, Stone RA, et al. Medical outcomes and antimicrobial costs with the use of the American Thoracic Society guidelines for outpatients with community-acquired pneumonia. JAMA 1997; 278: 32-9
31. 31. McGowan JE. Do intensive hospital antibiotic control programs prevent the spread of antibiotic resistance. Infect Control Hosp Epidemiol 1994; 15: 478-83
32. 32. Richard P, Delangle M, Merrien D, et al. Fluoroquinolone use and fluoroquinolone resistance: is there an association. Clin Infect Dis 1994; 19: 54-9
33. 33. Zhanel GG, Nicolle LE, Gin AS, et al. Ciprofloxacin or imipenem usage correlates with resistance in Pseudomonas aeruginosa. Can J Infect Dis 1998; 9: 382-6
34. 34. Jacobson KL, Cohen SH, Inciardi JF, et al. The relationship between antecedent antibiotic use and resistance to extended spectrum cephalosporins in Group 1 β-lactamase-producing organisms. Clin Infect Dis 1995; 21: 1107-13
35. 35. Ballow CH, Schentag JJ. Trends in antibiotic utilization and bacterial resistance. Report of the national nosocomial resistance surveillance group. Diagn Microbiol Infect Dis 1992; 15: 37S-42S
36. 36. Quale J, Landman D, Saurina G, et al. Manipulation of a hospital antimicrobial formulary to control an outbreak of vancomycin-resistant enterococci. Clin Infect Dis 1996; 23: 1020-5
37. 37. Seppala H, Klaukka T, Vuopio Varkila J, et al. The effect of changes in the consumption of macrolide antibiotics on the erythromycin resistance in group A streptococci in Finland. N Engl J Med 1997; 337: 441-6
38. 38. Baquero F. Trends in antibiotic resistance of respiratory pathogens: an analysis and commentary on a collaborative surveillance study. J Antimicrob Chemother 1996; 38 Suppl. A: 117-32
39. 39. Birkett DJ, Mitchell AS, Godeck A, et al. Profiles of antibacterial drug use in Australia and trends from 1987 to 1989. Med J Aust 1991; 155: 410-5
40. 40. Weiss MC, Fitzpatrick R, Scott DK, et al. Pressures on the general practitioner and decisions to prescribe. J Fam Pract 1996; 13: 432-8
41. 41. Kunin CM. The responsibility of the infectious disease community for the optimal use of antimicrobial agents. J Infect Dis 1985; 151: 388-98
42. 42. Norrby SR. Pharmacoeconomic studies on antibiotics: current controversies. Pharmacoeconomics 1994; 5: 274-7